Thermo Fisher Scientific (TMO) Valuation Check As New PRECISE Collaboration Targets Long Term Precision Medicine Growth

Thermo Fisher Scientific (TMO) is in focus after announcing a collaboration with Precision Health Research, Singapore for the PRECISE-SG100K biobank, connecting its proteomics platforms to a large population health effort.

See our latest analysis for Thermo Fisher Scientific.

Thermo Fisher’s recent biobank, cell therapy and structural biology announcements come against a mixed price backdrop, with a 6.84% 1 month share price return but a 16.27% decline year to date, while the 1 year total shareholder return sits at 10.82%.

If this kind of precision medicine story interests you, it may be worth checking tools that surface other healthcare names applying AI to diagnostics and research, including the 31 healthcare AI stocks.

With Thermo Fisher trading at US$496.11 compared with an average analyst target of US$654.60 and carrying a middling value score of 3, investors now have to ask whether there is real upside or if potential future growth is already reflected in the current price.

Most Popular Narrative: 8.2% Undervalued

According to a widely followed narrative by Unike, Thermo Fisher’s fair value of $540.27 sits above the last close at $496.11, framing a modest valuation gap that hinges on long run demand for life science tools.

Where Will TMO Be in 5 Years? TMO is well positioned to maintain its leadership in the life sciences industry, driven by R&D expansion, emerging market growth, and continued M&A. If margin expansion and revenue growth targets are met, the stock should continue compounding at a healthy rate.

Read the complete narrative.

Curious what underpins that premium to today’s price? The narrative leans on steady revenue expansion, higher profit margins and a future earnings multiple usually reserved for high confidence compounders.

Result: Fair Value of $540.27 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on biotech and pharma R&D spending not slowing materially and on Thermo Fisher continuing to integrate acquisitions without pressuring profitability.

Find out about the key risks to this Thermo Fisher Scientific narrative.

Another Take: Multiples Flag More Caution

Unike’s narrative points to an 8.2% gap between fair value of $540.27 and the current $496.11 price, but the P/E picture is less generous. TMO trades on 27.5x earnings versus a fair ratio of 26.4x, which suggests limited margin for error if sentiment shifts.

At the same time, the 27.5x P/E sits below both the peer average of 35.6x and the broader North American Life Sciences industry at 37.3x. This may signal that investors are already pricing in some risk. Where do you think the market is more likely to converge over time?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on valuation and sentiment, it makes sense to look at the numbers yourself and decide quickly how you see the balance of risks and rewards. To get a clearer picture before you act, review the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your goals even better, so put a few more ideas on your radar today.

• Target reliable income by scanning for companies with strong yields and resilience using the 11 dividend fortresses.
• Spot potential value opportunities early by reviewing the screener containing 23 high quality undiscovered gems before others catch on.
• Prioritise resilience and capital preservation by filtering for companies with lower risk profiles through the 73 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com